Protalix BioTherapeutics, Inc. PLX NYSE

Protalix BioTherapeutics, Inc. (PLX) generated $-11.99M in operating cash flow for fiscal year 2025. After capital expenditures of $1.64M, free cash flow was $-13.63M.

Free cash flow margin was -25.8% of revenue. Cash conversion ratio was 1.82x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (10/100) — Cash conversion ratio was 1.82x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.